Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2005
08/30/2005US6936633 Pyrrolidinone derivatives
08/30/2005US6936616 Pyrimidine matrix metalloproteinase inhibitors
08/30/2005US6936615 Heteroaryl derivatives and their use as medicaments
08/30/2005US6936612 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/30/2005US6936611 Serine protease inhibitors
08/30/2005US6936597 A conjugate of blocked polymer with a biologically active compound containing reactive hydroxy or amino groups
08/30/2005US6936595 Tumour-specific vector for gene therapy
08/30/2005US6936453 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof
08/30/2005US6936425 Attenuated salmonella SP12 mutants as antigen carriers
08/30/2005US6936424 Materials and methods for detection and treatment of breast cancer
08/30/2005US6936284 Composition having anticancer activity
08/30/2005US6936255 adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21
08/30/2005US6936253 Ganglioside-KLH conjugate vaccines plus QS-21
08/30/2005US6936248 Methods of inhibiting GPR-9-6 function
08/30/2005CA2294566C Ikk-.alpha. proteins, nucleic acids and methods
08/30/2005CA2202879C Calcium receptor-active compounds
08/30/2005CA2136331C New pharmaceutical uses of krill enzymes
08/30/2005CA2063587C Stable vaccine compositions containing interleukins
08/25/2005WO2005078087A1 Antibody targeting osteoclast-associated protein
08/25/2005WO2005077971A1 Novel heparin-binding peptide designed from heparin-binding site of snake poison-origin vascular endothelial growth factor (vegf)-like protein and use tehreof
08/25/2005WO2005077970A1 Novel heparin-binding peptide designed from heparin-binding site of snake venom-origin vascular endothelial growth factor (vegf)-like protein and use thereof
08/25/2005WO2005077912A1 Indazole compound and pharmaceutical use thereof
08/25/2005WO2005077910A1 Pyrazoline derivatives useful for the treatment of cancer
08/25/2005WO2005077900A1 Bicyclic amide derivatives
08/25/2005WO2005077887A1 Novel method of synthesis and novel crystalline form of agomelatine and pharmaceutical compositions containing said form
08/25/2005WO2005077421A1 A method of preparing polyethylene glycol modified interferon alpha 1b
08/25/2005WO2005077396A1 Drug for osteoporosis having inhibition effect on cancer comprising ginkgo biloba extracts as the active ingredient
08/25/2005WO2005077395A1 Physiologically active composition and process for producing the same
08/25/2005WO2005077366A1 Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells
08/25/2005WO2005077352A1 Use of 2,5-dihydroxybenzenesulphonic acid in the production of medicaments for the treatment of angiodependent diseases such as cancer and psoriasis
08/25/2005WO2005077351A1 Quinone remedies for lung diseases
08/25/2005US20050187291 use of 2-(urea or thiourea)tetralins as analgesic or to treat pulmonary dysfunction
08/25/2005US20050187273 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
08/25/2005US20050187271 and for reducing undesirable side effects of antitumor agents
08/25/2005US20050187270 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use
08/25/2005US20050187255 Novel curcumin analogues and uses thereof
08/25/2005US20050187236 Nitrogen-containing aromatic derivatives
08/25/2005US20050187228 Derivatives of purine, their preparation process and pharmaceutical compositions containing them
08/25/2005US20050187186 useful for the treatment of cancer and other hyperproliferative disorders; a sphingolipid; lactic acid; and optionally a stabilizing agent; emulsion
08/25/2005US20050187184 Administering CCI-779 [or 42-O-(2-hydroxy)ethyl rapamycin] and an aromatase inhibitor such as letrozole; therapy of neoplasms; useful in the treatment of renal cancer, soft tissue cancer, breast cancer, neuroendocrine tumor of the lung, cervical cancer, uterine cancer, head and neck cancer
08/25/2005US20050187179 treatment of tumors which have increased Notch expression; administration of either Notch antisense oligonucleotides or monoclonal antibodies directed to Notch along with cell differentiating agent
08/25/2005US20050187147 Compositions and methods for increasing drug efficiency
08/25/2005US20050186665 Expressed ligand - vascular intercellular signaling molecule
08/25/2005US20050186664 Albumin fusion proteins
08/25/2005US20050186663 Cystine-knot fold protein
08/25/2005US20050186660 Using calcitonin precursor protein as diagnostic tool in detection of cancer and sepsis
08/25/2005US20050186650 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
08/25/2005US20050186628 Dorsalin-1 polypeptide and uses thereof
08/25/2005US20050186626 Chicken leukemia inhibitory factor (LIF) and gene thereof
08/25/2005US20050186575 Corona-virus-like particles comprising functionally deleted genomes
08/25/2005US20050186571 Diagnosis and prevention of cancer cell invasion
08/25/2005US20050186568 Enzymatic polypeptides for use as drug screening tools; pharmacological toxicity
08/25/2005US20050186567 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
08/25/2005US20050186265 Negatively charged first lipid; barium, calcium, zinc, magnesium and/or cation; carbohydrates, vitamins, minerals, polynucleotides, polypeptides, lipids, flavors and drugs; particle sizes; storage stability, oxidation resistance, dimensional stability;
08/25/2005US20050186250 Metallic structures incorporating bioactive materials and methods for creating the same
08/25/2005US20050186215 CUDR as biomarker for cancer progression and therapeutic response
08/25/2005US20050186211 Use of mda-5 as an antiviral and antiproliferative agent
08/25/2005US20050186208 Anti-neoplastic composition of adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens; breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer, pancreatic cancer, soft-tissue sarcoma
08/25/2005US20050186205 Administering unlabelled anti-CD20 antibody that binds to the CD20 antigen present on lymphoma cells; a second treatment of cyclophosphamide, doxorubicin, vincristine or prednisone
08/25/2005US20050186203 Isolated antibody bound to human insulin-like growth factor-I receptor, identification of its CDRs (complementarity-determining regions), inhibiting the tyrosine kinase activity of the IGF-IR receptor
08/25/2005US20050186180 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug.
08/25/2005DE29924789U1 New, stable crystalline polymorph (form III) of the diuretic torasemide, by controlled acidification of alkaline solutions, has more rapid dissolution than form I
08/25/2005CA2566315A1 Use of non-peptide nk1 receptor antagonists for the production of apoptosis in tumour cells
08/25/2005CA2556601A1 The use of o-atp for the treatment of diseases involving angiogenesis
08/25/2005CA2556478A1 Pyrazoline derivatives useful for the treatment of cancer
08/25/2005CA2556400A1 Substituted pyrazoline compounds, their preparation and use as medicaments
08/25/2005CA2556254A1 Aqueous solution preparation containing camptothecins
08/25/2005CA2556069A1 Compounds having antitumor activity
08/25/2005CA2555866A1 Diagnostic markers for cancer
08/25/2005CA2555848A1 Antibody targeting osteoclast-associated protein
08/25/2005CA2555825A1 Process for the preparation of substituted triazole compounds
08/25/2005CA2555811A1 Methods for treating resistant or refractory tumors
08/25/2005CA2555791A1 Highly concentrated liquid formulations of anti-egfr antibodies
08/25/2005CA2555507A1 Use of proton pump inhibitors for the treatment of cancer conditions
08/25/2005CA2555503A1 Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
08/25/2005CA2555319A1 Inhibiting cav3 isoforms and the .delta.25b splice variants for the diagnosis and treatment of cancer
08/25/2005CA2555274A1 Chimeric vegf peptides
08/25/2005CA2555248A1 Use of 2,5 dihydroxybenzenesulfonic acid, in the manufacturing of medicines, applicable to the treatment of angiodependent diseases
08/25/2005CA2555227A1 Pyridazinone ureas as antagonists of .alpha.4 integrins
08/25/2005CA2555142A1 Cell proliferation associated with ccx ckr expression
08/25/2005CA2554974A1 Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
08/25/2005CA2554378A1 Bicycloamide derivative
08/25/2005CA2553889A1 7h-pyrrolopyrimidine derivatives
08/25/2005CA2553630A1 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
08/24/2005EP1566445A2 Viral core protein-cationic lipid-nucleic acid-delivery complexes
08/24/2005EP1566387A2 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
08/24/2005EP1566379A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
08/24/2005EP1565581A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
08/24/2005EP1565547A2 Probiotic strains, a process for the selection of them, compositions thereof, and their use
08/24/2005EP1565495A2 Anti-activated ras antibodies
08/24/2005EP1565491A2 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis
08/24/2005EP1565489A2 Novel raag10 cell surface target and a family of antibodies recognizing that target
08/24/2005EP1565487A2 Peptides binding the phosphatase 2a protein and polynucleotides encoding same
08/24/2005EP1565475A1 Diazinopyrimidines
08/24/2005EP1565474A2 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
08/24/2005EP1565471A1 Quinolinyl-pyrrolopyrazoles
08/24/2005EP1565467A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same
08/24/2005EP1565459A2 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
08/24/2005EP1565455A1 Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
08/24/2005EP1565446A1 Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
1 ... 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 ... 2211